Case Study: Genomics England achieves faster, lower-cost breast cancer genomics analysis with Lifebit

Genomics England cuts breast cancer analysis runtime by 70% with Lifebit

Genomics England faced significant challenges in analyzing large-scale genomic data for breast cancer research. The massive data volumes per genome, complex multi-stage analysis pipelines, and high computational demands resulted in extremely long runtimes, escalating costs, and slow scientific discovery cycles. To overcome these hurdles, they turned to Lifebit and its federated platform to power their research within a secure environment.

Lifebit implemented its federated platform to run large-scale clinico-genomic analyses inside Genomics England's secure research environment without moving patient data. This solution enabled the analysis of over 2,500 patient genomes, resulting in a 70% faster runtime for workflows and a 50% reduction in compute costs. The study, published in Lancet Oncology, identified actionable genomic findings in 27% of patients, a breakthrough with potential to benefit over 15,000 women diagnosed annually in the UK. Lifebit's platform was crucial in accelerating this translational research from insight to clinical application.

Genomics England